Delving into the Latest Updates on Shanghai Yuan Song Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Endocrinology and Metabolic Disease

Oncolytic virus

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	14
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Oncolytic virus	14

Top 5 Target	Count

IL-24(Interleukin 24)	1

主要目的评价YSCH-01用于治疗复发/难治性晚期实体瘤受试者的安全性/耐受性。确定YSCH-01临床推荐剂量。次要目的评价YSCH-01治疗复发/难治性晚期实体瘤的初步疗效。评估YSCH-01的生物分布和病毒脱落情况。评价接受YSCH-01受试者体内的药效学（PD）。评价接受YSCH-01受试者体内的免疫原性。初步评估YSCH-01对复发/难治性晚期实体瘤受试者生活质量的影响。

[Translation]

Primary Objectives Evaluate the safety/tolerability of YSCH-01 for the treatment of subjects with relapsed/refractory advanced solid tumors. Determine the recommended clinical dose of YSCH-01. Secondary Objectives Evaluate the preliminary efficacy of YSCH-01 in the treatment of relapsed/refractory advanced solid tumors. Evaluate the biodistribution and viral shedding of YSCH-01. Evaluate the pharmacodynamics (PD) in subjects receiving YSCH-01. Evaluate the immunogenicity in subjects receiving YSCH-01. Preliminary evaluation of the effect of YSCH-01 on the quality of life of subjects with relapsed/refractory advanced solid tumors.

Start Date17 Jun 2024

Sponsor / Collaborator

Shanghai Yuan Song Biotechnology Co., Ltd.

NCT05914935 / RecruitingEarly Phase 1IIT

Safety、Tolerability、Pharmacokinetics and Initial Efficacy of Recombinant L-IFN Adenovirus Injection in the Treatment of Recurrent Glioblastoma：an Open-label, Single-arm, Single-center, Multi-dose Investigator-initiated Clinical Trial

The target subjects were patients with histologically or cytologically confirmed recurrent glioblastoma.Six subjects were expected to be enrolled,the number of subjects will be adjusted according to the course and outcome of the trial.The aim of this study was to evaluate the safety and tolerability of recombinant L-IFN adenovirus injection in the treatment of patients with recurrent glioblastoma, and to determine the registered clinical recommended dose and dosing regimen.

Start Date27 Jun 2023

Sponsor / Collaborator

Shanghai Yuan Song Biotechnology Co., Ltd.

NCT05180851 / Unknown statusEarly Phase 1IIT

Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study

This is an open-label, dose escalation study of the safety and tolerability of Recombinant oncolytic adenovirus L-IFN injection（YSCH-01） when administered via intratumoral injection in patients with advanced solid tumors. The purpose of this study is to assess the safety and tolerability of Recombinant L-IFN adenovirus injectionand to determine the recommended phase 1 dose for further study. The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of Recombinant L-IFN adenovirus injection

Start Date30 Nov 2021

Sponsor / Collaborator

Shanghai Fengxian District Central Hospital

[+1]

100 Clinical Results associated with Shanghai Yuan Song Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Yuan Song Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Yuan Song Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Yuan Song Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

13

1

Phase 1 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

YSCH-01	Advanced Malignant Solid Neoplasm More	Phase 1
OncoMul-08	Solid tumor More	Preclinical
OncoMul-05	Solid tumor More	Preclinical
OncoMul-12	Solid tumor More	Preclinical
OncoMul-11	Solid tumor More	Preclinical